Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01216332 · ClinicalTrials.gov registry record · Phase 1
Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01216332 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 50 participants.
The verdict
NCT01216332, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a phase I safety and immunogenicity trial comparing high-dose (HD)trivalent inactivated influenza vaccine (TIV) to standard dose (SD) TIV in pediatric patients with Acute Lymphoblastic Leukemia.
Interventions
- DRUG High-dose trivalent inactivated influenza vaccine
- DRUG Standard dose trivalent inactivated influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01216332
The ClinicalTrials.gov registry entry for NCT01216332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which High-dose trivalent inactivated influenza vaccine is the first listed.
NCT01216332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01216332 about?
NCT01216332 is a clinical study titled "Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients". This is a phase I safety and immunogenicity trial comparing high-dose (HD)trivalent inactivated influenza vaccine (TIV) to standard dose (SD) TIV in pediatric patients with Acute Lymphoblastic Leukemia.
What is the current status of trial NCT01216332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2010-10. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01216332?
The interventions under investigation include: High-dose trivalent inactivated influenza vaccine (DRUG), Standard dose trivalent inactivated influenza vaccine (DRUG).
Who is sponsoring clinical trial NCT01216332?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.